CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
AUSTIN, Texas, Aug. 14, 2017 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 Wedbush PacGrow Healthcare Conference, taking place August 15-16 at the Le Parker Meridien hotel in New York City.
| Presentation Details: | ||
| Date: | Tuesday, August 15th | |
| Time: | 2:30pm Eastern Time | |
| Location: | Le Parker Meridien Hotel, Mirus Room | |
| Webcast: | http://wsw.com/webcast/wedbush33/mtem | |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
